Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06602258 · ClinicalTrials.gov registry record · Phase 2

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

A Phase 2 study of Alzheimers Disease, sponsored by Eisai.

Active
Registry status
Phase 2
Development phase
105
Enrollment target
20
Study locations

NCT06602258 is a Phase 2 study of Alzheimers Disease that is active but no longer recruiting, run by Eisai. The registered enrollment target is 105 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06602258, a Phase 2 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eisai.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
105 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG Lecanemab
  • DRUG E2814

Study Locations (20)

Florida

  • Bradenton Research Center - Bradenton
  • K2 Medical Research - Clermont
  • Advanced Clinical Research Network - Miami
  • Renstar Medical Research - Ocala
  • Progressive Medical Research - Port Orange
  • Alzheimer's Research and Treatment Center-Stuart - Stuart
  • Axiom Brain Health - Tampa
  • Charter Research - The Villages
  • Alzheimer's Research and Treatment Center - Wellington

Arizona

  • Banner Sun Health Research - Phoenix

Connecticut

  • Yale University School of Medicine - New Haven

Georgia

  • Columbus Memory Center, PC - Columbus

Mississippi

  • Hattiesburg Clinic - Hattiesburg

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • Abington Neurological Associates LTD - Abington

Tennessee

  • Neurology Clinic, P.C. - Cordova

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2024-09-30
Est. Completion 2027-08-18
Phase Phase 2

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06602258

The ClinicalTrials.gov registry entry for NCT06602258 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (97% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06602258 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06602258 about?

NCT06602258 is a clinical study titled "A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease". The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

What is the current status of trial NCT06602258?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2024-09-30. Estimated completion is 2027-08-18.

What conditions does trial NCT06602258 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT06602258?

The interventions under investigation include: Placebo (DRUG), Lecanemab (DRUG), E2814 (DRUG).

Who is sponsoring clinical trial NCT06602258?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06602258 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Georgia, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.